Somewhat Positive Press Coverage Somewhat Unlikely to Impact Meridian Bioscience (VIVO) Share Price
News headlines about Meridian Bioscience (NASDAQ:VIVO) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Meridian Bioscience earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave press coverage about the company an impact score of 48.1982788359616 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several brokerages recently weighed in on VIVO. Zacks Investment Research raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Saturday, April 29th. Canaccord Genuity raised their target price on shares of Meridian Bioscience from $13.00 to $15.00 and gave the company a “hold” rating in a report on Wednesday, May 3rd. Finally, BidaskClub cut shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Three research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. Meridian Bioscience has a consensus rating of “Hold” and a consensus price target of $14.75.
Shares of Meridian Bioscience (VIVO) opened at 13.65 on Friday. The firm’s 50-day moving average is $14.56 and its 200-day moving average is $14.00. Meridian Bioscience has a 12-month low of $10.75 and a 12-month high of $19.85. The firm has a market cap of $576.07 million, a PE ratio of 27.30 and a beta of 0.89.
Meridian Bioscience (NASDAQ:VIVO) last announced its earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.16. Meridian Bioscience had a return on equity of 16.93% and a net margin of 10.77%. The company had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. During the same period in the prior year, the company posted $0.21 EPS. Meridian Bioscience’s quarterly revenue was down 1.0% on a year-over-year basis. Equities analysts expect that Meridian Bioscience will post $0.67 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, August 17th. Shareholders of record on Monday, August 7th were given a $0.125 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.66%. The ex-dividend date was Thursday, August 3rd. Meridian Bioscience’s payout ratio is 98.04%.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.